Acorda Therapeutics (Amprya) Recognized by National Organization for Rare Disorders for Contribution to Treatment of Multiple Sclerosis
Acorda Therapeutics, Inc. today announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases. Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award will be presented tonight at the 2010 NORD Partners in Progress Gala in Washington, D.C.